Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients ; day:17 ; month:12 ; year:2023 ; pages:1-12
Cancer chemotherapy and pharmacology ; (17.12.2023), 1-12
- Creator
-
Westerdijk, K.
Krens, S. D.
Steeghs, N.
Graaf, W. T. A. van der
Tjwa, E. T. T. L.
Westdorp, H.
Desar, I. M. E.
Erp, N. P. van
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00280-023-04615-7
- URN
-
urn:nbn:de:101:1-2024030121075690606453
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Westerdijk, K.
- Krens, S. D.
- Steeghs, N.
- Graaf, W. T. A. van der
- Tjwa, E. T. T. L.
- Westdorp, H.
- Desar, I. M. E.
- Erp, N. P. van
- SpringerLink (Online service)
Other Objects (12)
Disease Response to Pazopanib in Follicular Dendritic Cell Sarcoma
Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort
A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report
Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
Reversible Hypopigmentation with Pazopanib
Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
Neoadjuvant pazopanib treatment in high-risk soft tissue sarcoma: a quantitative dynamic 18F-FDG PET/CT study of the German Interdisciplinary Sarcoma Group
Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma
Disease Response to Pazopanib in Follicular Dendritic Cell Sarcoma
Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort
A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report
Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
Reversible Hypopigmentation with Pazopanib
Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
Neoadjuvant pazopanib treatment in high-risk soft tissue sarcoma: a quantitative dynamic 18F-FDG PET/CT study of the German Interdisciplinary Sarcoma Group
Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma
Disease Response to Pazopanib in Follicular Dendritic Cell Sarcoma
Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort
A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report
Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
Reversible Hypopigmentation with Pazopanib
Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
Neoadjuvant pazopanib treatment in high-risk soft tissue sarcoma: a quantitative dynamic 18F-FDG PET/CT study of the German Interdisciplinary Sarcoma Group